# US 2019/0309285 A1 · Genes expressed in mental illness and mood disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0309285 A1
- Document ID: US20190309285A1
- Status: Published application
- Kind: A1
- Application number: 16/378,233
- Filed: 2019-04-08
- Published: 2019-10-10
- Earliest claimed: 2013-03-01
- Assignees: PsychNostics, LLC
- Applicants: PsychNostics, LLC
- Inventors: Alagu P. THIRUVENGADAM; Krish CHANDRASEKARAN
- Web page: https://patentgrep.com/patent/US20190309285A1

## CPC

- C12N 15/1034: {Isolating an individual clone by screening libraries}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C40B 40/06: Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

The present invention relates to a composition comprising a plurality of cDNA molecules for use in methods of detecting changes in expression of genes encoding proteins that are associated with mental illnesses and which are differentially expressed in patients with mental illnesses, such as bipolar I disorder, bipolar II disorder, unipolar disorder, schizophrenia. attention deficit hyperactive disorders, obsessive compulsive disorders, anxiety disorders or other related mood disorders. The composition and the cDNA molecules may be used in their entirety or in part as to diagnose. to stage, to treat. and/or to monitor the treatment of a subject with mental illness.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A method for treating mental illness comprising:
obtaining a sample containing nucleic acid transcripts from a subject;
combining the sample with a composition comprising a plurality of cDNA molecules, wherein the plurality of cDNA molecules consists of two or more cDNA molecules selected from the group consisting of SEQ ID NOs:1-50, wherein one or more of SEQ ID NOs:1-50 may be substituted for by the complement of said cDNA molecule, to form one or more hybridization complexes;
detecting the one or more hybridization complexes;
comparing the one or more hybridization complexes detected with those from a subject without a mental illness, wherein differences in the intensity of each hybridization complex indicates differential expression of cDNAs in the sample;
identifying the subject to have a mental illness based on the differential expression of cDNAs in the sample; and
administering to the subject a treatment for the mental illness.

### Claim 25

A method for treating mental illness comprising:
obtaining a sample containing nucleic acids from a subject;
combining the sample with an array comprising a plurality of cDNA molecules immobilized on a substrate, wherein the plurality of cDNA molecules consists of two or more cDNA molecules selected from the group consisting of SEQ ID NOs:1-50, wherein one or more of SEQ ID NOs: 1-50 may be substituted for by the complement of said cDNA molecule, to form one or more hybridization complexes;
detecting the one or more hybridization complexes;
comparing the one or more hybridization complexes detected with those from a subject without a mental illness, wherein differences in the intensity of each hybridization complex indicates differential expression of cDNAs in the sample;
identifying the subject to have a mental illness based on the differential expression of cDNAs in the sample; and
administering to the subject a treatment for the mental illness.

### Claim 26 (depends on 24, 25)

The method of claim 24 or 25, wherein said plurality of cDNA molecules consists of SEQ ID NOs: 1-8, wherein one or more of SEQ ID NOs:1-8 may be substituted for by the complement of said cDNA molecule.

### Claim 27 (depends on 24, 25)

The method of claim 24 or 25, wherein said plurality of cDNA molecules consists of SEQ ID NOs:1-15, wherein one or more of SEQ ID NOs:1-15 may be substituted for by the complement of said cDNA molecule.

### Claim 28 (depends on 25)

The method of claim 25, wherein said substrate is selected from the group consisting of a nylon membrane, a nitrocellulose membrane, a polypropylene support, a glass support and a silicon support.

### Claim 29 (depends on 24, 25)

The method of claim 24 or 25, wherein the sample is blood or is obtained by separation from blood.

### Claim 30 (depends on 24, 25)

The method of claim 24 or 25, wherein said nucleic acids are amplified prior to hybridization.

### Claim 31 (depends on 24, 25)

The method of claim 24 or 25, wherein said differential expression is a downregulation of at least two-fold in said sample from said subject with a mental illness.

### Claim 32 (depends on 24, 25)

The method of claim 24 or 25, wherein the mental illness is selected from the group consisting of bipolar I disorder, bipolar II disorder, unipolar disorder, schizophrenia, an attention deficit hyperactive disorder, an obsessive compulsive disorder, an anxiety disorder and a mood related disorder.

### Claim 33

A method of monitoring treatment for mental illness comprising
obtaining a sample containing nucleic acids from a subject treated for mental illness;
combining the sample with a composition comprising a plurality of cDNA molecules, wherein the plurality of cDNA molecules consists of two or more cDNA molecules selected from the group consisting of SEQ ID NOs:1-50, wherein one or more of SEQ ID NOs:1-50 may be substituted for by the complement of said cDNA molecule, to form one or more hybridization complexes;
detecting the one or more hybridization complexes;
comparing the one or more hybridization complexes detected with those from a subject without a mental illness, wherein differences in the intensity of each hybridization complex indicates differential expression of cDNAs in the sample; and
altering treatment for the subject treated for mental illness when differential expression of cDNAs in the sample is detected.

### Claim 34

A method of monitoring treatment for mental illness comprising
obtaining a sample containing nucleic acids from a subject treated for mental illness;
combining the sample with an array comprising a plurality of cDNA molecules immobilized on a substrate, wherein the plurality of cDNA molecules consists of two or more cDNA molecules selected from the group consisting of SEQ ID NOs:1-50, wherein one or more of SEQ ID NOs: 1-50 may be substituted for by the complement of said cDNA molecule, to form one or more hybridization complexes;
detecting the one or more hybridization complexes;
comparing the one or more hybridization complexes detected with those from a subject without a mental illness, wherein differences in the size and intensity of each hybridization complex indicates differential expression of cDNAs in the sample; and
altering treatment for the subject treated for mental illness when differential expression of cDNAs in the sample is detected.

### Claim 35 (depends on 33, 34)

The method of claim 33 or 34, wherein said plurality of cDNA molecules consists of SEQ ID NOs: 1-8, wherein one or more of SEQ ID NOs:1-8 may be substituted for by the complement of said cDNA molecule.

### Claim 36 (depends on 33, 34)

The method of claim 33 or 34, wherein the plurality of cDNA molecules consists of SEQ ID NOs:1-15, wherein one or more of SEQ ID NOs:1-15 may be substituted for by the complement of said cDNA molecule.

### Claim 37 (depends on 33, 34)

The method of claim 33 or 34, wherein said plurality of cDNA molecules consists of SEQ ID NOs: 1-8, wherein one or more of SEQ ID NOs:1-8 may be substituted for by the complement of said cDNA molecule.

### Claim 38 (depends on 33, 34)

The method of claim 33 or 34, wherein said plurality of cDNA molecules consists of SEQ ID NOs:1-15, wherein one or more of SEQ ID NOs:1-15 may be substituted for by the complement of said cDNA molecule.

### Claim 39 (depends on 34)

The method of claim 34, wherein the substrate is selected from the group consisting of a nylon membrane, a nitrocellulose membrane, a polypropylene support, a glass support and a silicon support.

### Claim 40 (depends on 33, 34)

The method of claim 33 or 34, wherein the sample is blood or is obtained by separation from blood.

### Claim 41 (depends on 33, 34)

The method of claim 33 or 34, wherein the nucleic acids are amplified prior to hybridization.

### Claim 42 (depends on 33, 34)

The method of claim 33 or 34, wherein said differential expression is a downregulation of at least two-fold in said sample from said subject with a mental illness.

### Claim 43 (depends on 33, 34)

The method of claim 33 or 34, wherein the mental illnesses is selected from the group consisting of bipolar I disorder, bipolar II disorder, unipolar disorder, schizophrenia, an attention deficit hyperactive disorder, an obsessive compulsive disorder, an anxiety disorder and a mood related disorder.